EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment

Erik Stenberg iD, Johan Ottosson, Yang Cao, Magnus Sundbom, Erik Näslund iD

British Journal of Surgery · 30.08.2024 · 111 (9)

DOI: 10.1093/bjs/znae221 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift British Journal of Surgery, online erschienen am 05.09.2024. Verfasst von Erik Stenberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden. Hauptthemen laut MEDLINE: Bariatric Surgery, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With the increasing prevalence of obesity and type 2 diabetes, the availability of different treatment options remains essential. Studies comparing the outcomes of glucagon-like peptide 1 receptor agonists with those of metabolic bariatric surgery in patients with type 2 diabetes and obesity are lacking.

Methods

Using propensity score matching, based on data from several nationwide clinical registries, patients who underwent primary metabolic bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) were matched with patients who received glucagon-like peptide 1 receptor agonists. Outcome measures included the occurrence of major cardiovascular events, microvascular complications, and potential side effects (alcohol/substance abuse, self-harm, and fractures).

Results

Over a mean follow-up of 7 years, major cardiovascular events occurred in 191 of 2039 patients (cumulative incidence 14.5%) in the surgery group compared with 247 of 2039 patients (19.6%) in the glucagon-like peptide 1 receptor agonist group (HR 0.75 (95% c.i. 0.62 to 0.91), P = 0.003). Patients in the surgery group had lower haemoglobin A1c values 5 years after treatment (mean difference 9.82 (95% c.i. 8.51 to 11.14) mmol/mol, P < 0.001) and fewer microvascular complications (retinopathy HR 0.88 (95% c.i. 0.79 to 0.99), P = 0.039; nephropathy HR 0.72 (95% c.i. 0.66 to 0.80), P < 0.001; and neuropathy or leg ulcers HR 0.82 (95% c.i. 0.74 to 0.92), P < 0.001), but a higher risk of alcohol/substance abuse (HR 2.56 (95% c.i. 1.87 to 3.50), P < 0.001), self-harm (HR 1.41 (95% c.i. 1.17 to 1.71), P < 0.001), and fractures (HR 1.86 (95% c.i. 1.11 to 3.12), P = 0.019).

Conclusion

Compared with glucagon-like peptide 1 receptor agonist treatment, metabolic bariatric surgery is associated with superior metabolic outcomes and a lower risk of major cardiovascular events in patients with type 2 diabetes and obesity, but a higher risk of alcohol/substance abuse, self-harm, and fractures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryCardiovascular DiseasesDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsAdultFemaleHumansMaleMiddle AgedHypoglycemic AgentsObesityObesity, MorbidPostoperative ComplicationsPropensity ScoreTreatment Outcome

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Surgery, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden.
  • Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
  • Division of Surgery, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Erik Stenberg, Erik Näslund

Zitieren

APA

Stenberg, E., Ottosson, J., Cao, Y., Sundbom, M., & Näslund, E. (2024). Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment. British Journal of Surgery, 111(9). https://doi.org/10.1093/bjs/znae221

Vancouver

Stenberg E, Ottosson J, Cao Y, Sundbom M, Näslund E. Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment. British Journal of Surgery. 2024;111(9). doi:10.1093/bjs/znae221

BibTeX
@article{Stenberg2024,
  author = {Stenberg, Erik and Ottosson, Johan and Cao, Yang and Sundbom, Magnus and Näslund, Erik},
  title = {Cardiovascular and diabetes outcomes among patients with obesity and type 2 diabetes after metabolic bariatric surgery or glucagon-like peptide 1 receptor agonist treatment},
  journal = {British Journal of Surgery},
  year = {2024},
  volume = {111},
  number = {9},
  doi = {10.1093/bjs/znae221}
}
Kostenlos starten →